Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9548473 | 0.83 | CYP2A6 (0.50) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL17398007 | 0.83 | CYP2A6 (0.38) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL30849345 | 0.77 | DDAH1 (0.46) | ALDH1A1MAPTLMNAHPGDCYP19A1 | |
| SCHEMBL11479924 | 0.77 | DDAH1 (0.46) | ALDH1A1MAPTLMNAHPGDCYP19A1 | |
| SCHEMBL28034439 | 0.75 | DDAH1 (0.64) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL28423177 | 0.74 | CHRNA7 (0.46) | ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL1958579 | 0.74 | POLB (0.44) | ALDH1A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL1962185 | 0.73 | TSHR (0.57) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL17233525 | 0.72 | MEN1 (0.55) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL8736791 | 0.72 | SMN1; SMN2 (0.43) | MEN1KMT2AMAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-7504401-B2 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | ALDH1A1 731/4885MEN1 2463/4885KMT2A 2531/4885 |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | ALDH1A1 659/4885MEN1 2359/4885KMT2A 2491/4885 |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | NR2E3, RB1, CBR3 | ALDH1A1 489/4885MEN1 1354/4885KMT2A 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.